675 related articles for article (PubMed ID: 10630643)
1. The role of cyclooxygenases in inflammation, cancer, and development.
Williams CS; Mann M; DuBois RN
Oncogene; 1999 Dec; 18(55):7908-16. PubMed ID: 10630643
[TBL] [Abstract][Full Text] [Related]
2. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
4. [COX-2 inhibitor and colon cancer].
Tsujii M
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1799-805. PubMed ID: 11729471
[TBL] [Abstract][Full Text] [Related]
5. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
Evans JF
Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
[TBL] [Abstract][Full Text] [Related]
6. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Sanborn R; Blanke CD
Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathology of cyclooxygenase-2 in neoplasia.
Fosslien E
Ann Clin Lab Sci; 2000 Jan; 30(1):3-21. PubMed ID: 10678579
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production.
Johnson PM; Vogt SK; Burney MW; Muglia LJ
Am J Physiol Endocrinol Metab; 2002 Mar; 282(3):E650-6. PubMed ID: 11832369
[TBL] [Abstract][Full Text] [Related]
11. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
Xu H; Izon DJ; Loftin C; Spain LM
Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
[TBL] [Abstract][Full Text] [Related]
12. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
[TBL] [Abstract][Full Text] [Related]
13. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Lipsky PE
J Rheumatol Suppl; 1999 Apr; 56():25-30. PubMed ID: 10225537
[TBL] [Abstract][Full Text] [Related]
14. Approach to angiogenesis inhibition based on cyclooxygenase-2.
Masferrer J
Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cyclo-oxygenase-2.
Stack E; DuBois RN
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Shattuck-Brandt RL; Lamps LW; Heppner Goss KJ; DuBois RN; Matrisian LM
Mol Carcinog; 1999 Mar; 24(3):177-87. PubMed ID: 10204802
[TBL] [Abstract][Full Text] [Related]
17. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
[TBL] [Abstract][Full Text] [Related]
19. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
Hartwich J; Konturek SJ; Pierzchalski P; Zuchowicz M; Konturek PC; Bielański W; Marlicz K; Starzyńska T; Ławniczak M
Med Sci Monit; 2001; 7(6):1171-81. PubMed ID: 11687726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
